Yu Lu, VP Business Operations at STA Pharmaceutical, a WuXi AppTec company, explains how the company has established its technological platforms for the oligos and peptides market and where it sees the field developing in the future.
This interview was filmed as part of TIDES TV at TIDES US in San Diego, CA, May 20-23, 2019.
Join us at TIDES Europe, Amsterdam, 12-15 November 2019: https://bit.ly/2IoyYP2
More info on Creating technologies for the peptides and oligonucleotides field – STA Pharmaceutical
Current Trends in the Use of Liposomes for Tumor Targeting
Benzoporphyrin photosensitizer-encapsulated PEGylated liposomes, modified with a peptide (Ala-Pro-Arg-Pro ... to a high-frequency alternating magnetic field, which ruptured the liposomes and ...
The Promise of Nanomedicine for Ocular Disease
Therefore, pharmaceutical industries will support ... and inherited retinal dystrophies have demonstrated that new medical technologies can be rapidly and successfully translated into clinically ...
Digital technologies have impacted ... the ability to reliably detect low-abundance peptides of interest while screening out unwanted noise. High-field asymmetric waveform ion mobility ...
Publications of ScopeM staff
Silicon oxycarbide (SiOC) has recently regained attention in the field of Li-ion batteries ... Marc-Georg Willinger and Javier Pérez-Ramírez Catalysis Science & Technology, vol. 10: no. 12, pp.
Chemical glycobiology: why now?
Similarly, consortia have provided technology platforms and focus to a burgeoning field. Now ... much more difficult to handle than oligonucleotides and peptides. Beyond this first level of ...
Nanocarriers as an emerging platform for cancer therapy
Targeting agents can be broadly classified as proteins (mainly antibodies and their fragments), nucleic acids (aptamers), or other receptor ligands (peptides, vitamins, and carbohydrates).